Novel Method for Greatly Increasing Liposomal Drug Delivery to Lymph Nodes

Tech ID:
1998.018.HSCS
Description:

This invention provides a method of targeting colloids to the lymph nodes and retaining the colloids in the lymph nodes for an extended period of time.  The colloids can be used for imaging and/or for delivery of therapeutic agents.  The sentinel lymph node is the first lymph node encountered by metastatic tumor cells that have escaped from the primary tumor site.  In the sentinel lymph node the tumor cells are recognized by the immune system and in most cases destroyed.  Occasionally tumor cells survive in the sentinel lymph node and this then acts as a reservoir from which metastatic tumor cells spread throughout the body.  For this reason it is important that surgeons map the lymphatic drainage from a primary tumor site and biopsy the sentinel lymph node. 

 

Background:

Detection of lymph nodes has previously been accomplished using radiolabeled colloids to passively target the lymphatic system followed by scintigraphic scans or radio-guided probes to locate the most radioactive area.  Vital Blue dye has also been used to map lymphatic drainage but is rapidly cleared.  This invention provides a method of targeting colloids to the lymph nodes and retaining the colloids in the lymph nodes for an extended period of time.  The colloids can be used for imaging and/or for delivery of therapeutic agents.

 

Applications/Advantages: 

·         Imaging: The colloids can be labeled with contrast agents for scintigraphy, MRI, X-ray, CT or ultrasound imaging. The colloids can also be co-labeled with Vital Blue dye.  The prolonged retention time allows for visualization of intensely blue lymph nodes.

·         Imaging / Therapeutic: The prolonged retention time in the lymph node (>20 hrs) allows for improved imaging and delivery of therapeutic products.

·         Radiation Therapy: Can be labeled with radiosensitizers, radioprotecters, photodynamic agents or neutron capture agents.

·         Delivery of therapeutic agents: Can be used to target vaccines, DNA, RNA, peptides, biological response modifiers, antimicrobials, antivirals, antitumor agents or cytotoxic agents.

·         Can be incorporated into detection/therapeutic kits.

·         Decreased toxicity and cost of therapy due to reduction in required dosage amounts.

 

Availability: 

Available for exclusive licensing.

Patent Information:
Category(s):
Imaging
For information contact:
Carolyn Buller
Business Development Manager
Office of Technology Commercialization
Buller@uthscsa.edu
Inventors:
Beth Goins
William Phillips
Keywords:
Drugs